Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial (NORD-STAR).
Kristina LendFrieda A KoopmanJon LampaGerrit JansenMerete Hetland LTill UhligDan NordströmMichael T NurmohamedBjorn GudbjornssonAnna RudinMikkel ØstergaardMarte S HeibergTuulikki Sokka-IslerKim Hørslev-PetersenEspen A HaavardsholmGerdur GrondalJos W R TwiskRonald van VollenhovenPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Methotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/week, and these were more frequent in combination with tocilizumab versus active conventional treatment. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24 weeks. This article is protected by copyright. All rights reserved.
Keyphrases
- rheumatoid arthritis
- high dose
- disease activity
- systemic lupus erythematosus
- randomized controlled trial
- clinical trial
- combination therapy
- ankylosing spondylitis
- rheumatoid arthritis patients
- systemic sclerosis
- interstitial lung disease
- study protocol
- idiopathic pulmonary fibrosis
- preterm birth
- placebo controlled